Liposome-stabilized oil-in-water emulsions as adjuvants: Increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen

被引:14
作者
Richards, RL
Rao, M
Vancott, TC
Matyas, GR
Birx, DL
Alving, CR
机构
[1] Walter Reed Army Inst Res, Dept Membrane Biochem, Silver Spring, MD USA
[2] Walter Reed Army Inst Res, Div Retrovirol, Silver Spring, MD USA
[3] Henry M Jackson Fdn, Rockville, MD USA
关键词
adjuvant; CTL; emulsion; HIV; liposomes;
D O I
10.1111/j.0818-9641.2004.01282.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Protective or therapeutic immunity against HIV infection is currently believed to require both antibody and CTL responses against the envelope protein. In the present study, the adjuvant activity of a unique oil-in-water emulsion, in which liposomes containing lipid A (LA) and encapsulated antigen served as the emulsifying agent, was examined in mice using oligomeric gp140 (ogp140) derived from the HIV-1 envelope as the antigen. Emulsions rendered either highly stable or unstable by altering the ratio of liposomes to oil were used to examine the effect of stability of the emulsion on adjuvant activity. Stable and unstable emulsions had similar potencies for inducing both IgG antibodies to ogp140 and antigen-specific T-lymphocyte proliferation. Stable emulsions, but not unstable emulsions, induced antigen-specific CTL responses, possibly because of the depot effect of the stable emulsions. Furthermore, stable emulsions induced lower IgG2a/IgG1 ratios than the unstable emulsions. We conclude that stable liposomal oil-in-water emulsions provide an effective means of obtaining both antibody and CTL responses against an HIV envelope antigen.
引用
收藏
页码:531 / 538
页数:8
相关论文
共 31 条
[1]  
ALVING CR, 1994, AIDS RES HUM RETROV, V10, pS91
[2]   Design and selection of vaccine adjuvants: animal models and human trials [J].
Alving, CR .
VACCINE, 2002, 20 :S56-S64
[3]   LIPOSOMES AS CARRIERS OF PEPTIDE ANTIGENS - INDUCTION OF ANTIBODIES AND CYTOTOXIC T-LYMPHOCYTES TO CONJUGATED AND UNCONJUGATED PEPTIDES [J].
ALVING, CR ;
KOULCHIN, V ;
GLENN, GM ;
RAO, M .
IMMUNOLOGICAL REVIEWS, 1995, 145 :5-31
[4]  
ALVING CR, 1993, LIPOSOME TECHNOLOGY, V3, P317
[5]   DEVELOPMENT OF ARTIFICIAL VACCINES AGAINST HIV USING DEFINED EPITOPES [J].
BERZOFSKY, JA .
FASEB JOURNAL, 1991, 5 (10) :2412-2418
[6]  
EDELMAN R, 1980, REV INFECT DIS, V2, P370
[7]   ADJUVANTS FOR HUMAN VACCINES - CURRENT STATUS, PROBLEMS AND FUTURE-PROSPECTS [J].
GUPTA, RK ;
SIBER, GR .
VACCINE, 1995, 13 (14) :1263-1276
[8]   ADJUVANTS - A BALANCE BETWEEN TOXICITY AND ADJUVANTICITY [J].
GUPTA, RK ;
RELYVELD, EH ;
LINDBLAD, EB ;
BIZZINI, B ;
BENEFRAIM, S ;
GUPTA, CK .
VACCINE, 1993, 11 (03) :293-306
[9]  
Harris DT, 1999, SEMIN ONCOL, V26, P439
[10]   Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes [J].
Heppner, DG ;
Gordon, DM ;
Gross, M ;
Wellde, B ;
Leitner, W ;
Krzych, U ;
Schneider, I ;
Wirtz, RA ;
Richards, RL ;
Trofa, A ;
Hall, T ;
Sadoff, JC ;
Boerger, P ;
Alving, CR ;
Sylvester, DR ;
Porter, TG ;
Ballou, WR .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (02) :361-366